Journal Article

Utility of positron emission tomography for drug development for heart failure

Yaddanapudi, Kavitha, Skopicki, Hal A., Gheorghiade, Mihai, Marti, Catherine N., Papadimitriou, Lampros, Sarwar, Chaudhry M.S., Smith-Jones, Peter M., Parsey, Ramin, Butler, Javed

2016

Overview

Only about 1 in 5,000 investigational agents in a preclinical stage acquires Food and Drug Administration approval. Among many reasons for this includes an inefficient transition from preclinical to clinical phases, which exponentially increase the cost and the delays the process of drug development. Positron emission tomography (PET) is a nuclear imaging technique that has been used for the diagnosis, risk stratification, and guidance of therapy. However, lately with the advance of radiochemistry and of molecular imaging technology, it became evident that PET could help novel drug development process. By using a PET radioligand to report on receptor occupancy during novel agent therapy, it may help assess the effectiveness, efficacy, and safety of such a new medication in an early preclinical stage and help design successful clinical trials even at a later phase. In this article, we explore the potential implications of PET in the development of new heart failure therapies and review PET's application in the respective pathophysiologic pathways such as myocardial perfusion, metabolism, innervation, inflammation, apoptosis, and cardiac remodeling.

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Cardiovascular / Cardiovascular Agents - pharmacology / Drug Design / Drug dosages / Drug Evaluation, Preclinical - methods / Heart failure / Heart Failure - drug therapy / Ligands / Medical imaging / Metabolism / Pharmaceutical industry / Positron-Emission Tomography - methods / Studies / Tissue Distribution